Autifony Therapeutics announces £3.3 million collaboration to progress first-in-class drug for schizophrenia into clinical trials

Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced a £3.3 million collaborative project to progress its new drug, AUT00206 into clinical trials for the treatment of schizophrenia. £2.4 million will come from the Biomedical Catalyst, jointly funded by Innovate UK and the Medical Research Council.

Read More